JMP Securities downgraded Adicet Bio from Mkt Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2024 | $7.00 | Buy | Guggenheim |
| 9/11/2024 | Buy → Neutral | H.C. Wainwright | |
| 6/27/2023 | Buy → Neutral | Guggenheim | |
| 6/27/2023 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 6/1/2023 | $20.00 → $6.00 | Overweight → Neutral | JP Morgan |
| 9/21/2022 | $23.00 | Overweight | JP Morgan |
| 3/31/2022 | $28.00 | Outperform | SMBC Nikko |
| 3/8/2022 | $30.00 | Buy | Truist Securities |
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
SCHEDULE 13D/A - Adicet Bio, Inc. (0001720580) (Subject)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00
H.C. Wainwright downgraded Adicet Bio from Buy to Neutral
Guggenheim downgraded Adicet Bio from Buy to Neutral
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2025. Five individuals were hired by Adicet in October 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 97,200 shares of Adicet's common stock with an exercise price of $0.75 per share, the closing price of Adicet's common stock as reported by Nasdaq on October 31, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the rema
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston. Details of the event are as follows: Date: Tuesday, November 11, 2025 Time: 3:00 p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio,
Preliminary clinical data from the Phase 1 trial expected in 2H/2026 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA. "Dosing the first patient in our clinical study of ADI-001 in treatment-refractory RA marks an important milestone in our Phase 1 program, which is now enrolling across seven autoimmune conditions," said Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio. "In this study we are evaluating two conditioning regimens
--Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive
Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. "We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the c
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo
-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE patients experienced rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician's Global Assessment (PGA) highlighting ADI-001's potential for durable effect on a broad range of lupus symptoms- -As of the August 31, 2025 data cut-off date, all five LN patients experienced improved renal function, including three complete renal responses and Definition Of Remission In Systemic lupus erythematosus (DORIS) rem
Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)